Phase 2 Lung Cancer Trial, Recruiting NCT05849129 Sponsor: The Canadian College of Naturopathic Medicine Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT05849129
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are seen at TOHCC and have been diagnosed with advanced lung cancer (specifically stage IIIB or stage IV non-small cell lung cancer)
  • People who are scheduled to receive their first course of platinum-based chemotherapy, with or without immunotherapy at the same time

Who may not be able to join:

  • People whose physical functioning and ability to care for themselves is significantly limited (based on a standard medical scoring system — confirm with trial site)
  • People who have received intravenous vitamin C (IVC) within the 6 months before joining the trial
  • People who have a condition called G6PD deficiency, which affects how the body processes certain substances
  • People whose kidneys are not filtering blood well enough (a kidney function measurement below a certain level — confirm with trial site)
  • People who are currently taking insulin or the blood-thinning medication warfarin
  • People with a history of severe kidney problems or a condition called hemochromatosis (a condition involving too much iron in the body)
  • People who have received chemotherapy or immunotherapy within the 12 months before joining the trial
  • People who are pregnant or planning to become pregnant and carry a gene linked to G6PD deficiency
  • People who are currently taking part in another clinical trial or have done so in the past 30 days
  • People who, for any other reason, the lead doctor overseeing the trial considers unsuitable to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 613-792-1222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The Canadian College of Naturopathic Medicine
Registry
ClinicalTrials.gov
Start date
1 October 2024
Est. completion
1 October 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Change in Quality of Life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov